Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth

Cancer Gene Therapy

Volumn 14, Issue 6, 2007, Pages 583-589

  Horiguchi, A ^a   Zheng, R ^a   Goodman, O B ^a   Shen, R ^a   Guan, H ^b   Hersh, L B ^b   Nanus, D M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Lentivirus; Neprilysin; Prostate cancer

Indexed keywords

FOCAL ADHESION KINASE; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; MEMBRANE METALLOENDOPEPTIDASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE TRANSFER; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEPRILYSIN; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

LENTIVIRUS;

EID: 34249089882     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701047     Document Type: Article

References (28)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998; 4: 50-57.
3. Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG et al. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000; 6: 1664-1670.
4. Osman I, Yee H, Taneja SS, Levinson B, Zeleniuch-Jacquotte A, Chang C et al. Neutral endopeptidase protein expression and prognosis in localized prostate cancer. Clin Cancer Res 2004; 10: 4096-4100.
5. Sumitomo M, Milowsky MI, Shen R, Navarro D, Dai J, Asano T et al. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 2001; 61: 3294-3298.
6. Goodman OG, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein RL et al. Neutral endopeptidase inhibits angiogenesis via proteolysis of basic fibroblast growth factor (FGF-2). J Biol Chem 2006; 281: 33597-33605.
7. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000; 106: 1399-1407.
8. Iwase A, Shen R, Navarro D, Nanus DM. Direct binding of neutral endopeptidase 24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J Biol Chem 2004; 279: 11898-11905.
9. Sumitomo M, Iwase A, Zheng R, Navarro D, Kaminetzky D, Shen R et al. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 2004; 5: 67-78.
10. Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D et al. Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin Cancer Res 2001; 7: 1370-1377.
11. MacRae EJ, Giannoudis A, Ryan R, Brown NJ, Hamdy FC, Maitland N et al. Gene therapy for prostate cancer: current strategies and new cell-based approaches. Prostate 2006; 66: 470-494.
12. Pellinen R, Hakkarainen T, Wahlfors T, Tulimaki K, Ketola A, Tenhunen A et al. Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy. Int J Oncol 2004; 25: 1753-1762.
13. Bastide C, Maroc N, Bladou F, Hassoun J, Maitland N, Mannoni P et al. Expression of a model gene in prostate cancer cells lentivirally transduced in vitro and in vivo. Prostate Cancer Prostatic Dis 2003; 6: 228-234.
14. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 2001; 8: 628-635.
15. Yu D, Jia WW, Gleave ME, Nelson CC, Rennie PS. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter. Prostate 2004; 59: 370-382.
16. Zheng JY, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther 2003; 10: 764-770.
17. Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005; 11: 346-352.
18. Jiang G, Li J, Zeng Z, Xian L. Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther 2006; 5: 435-440.
19. Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 2006; 13: 1023-1032.
20. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 2004; 23: 6031-6039.
21. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2003; 23: 1992-1996.
22. Coleman JE, Huentelman MJ, Kasparov S, Metcalfe BL, Paton JF, Katovich MJ et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003; 12: 221-228.
23. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M et al. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 2000; 141: 1699-1704.
24. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Hayakawa M. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004; 10: 8648-8655.
25. Sramkoski RM, Pretlow II TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS et al. A new human prostate carcinoma cell line, 22Rv1. In vitro Cell Dev Biol Anim 1999; 35: 403-409.
26. Marr RA, Guan H, Rockenstein E, Kindy M, Gage FH, Verma I et al. Neprilysin regulates amyloid beta peptide levels. J Mol Neurosci 2004; 22: 5-11.
27. Sumitomo M, Asano T, Asakuma J, Nanus DM, Hayakawa M. Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. Clin Cancer Res 2004; 10: 260-266.
28. Chapel-Fernandes S, Jordier F, Lauro F, Maitland N, Chiaroni J, de Micco P et al. Use of the PSA enhancer core element to modulate the expression of prostate-and non-prostate-specific basal promoters in a lentiviral vector context. Cancer Gene Ther 2006; 13: 919-929.